AbbVie Inks $5.8B Deal For Cancer Drug Maker Stemcentrx
AbbVie Inc. will buy drug maker Stemcentrx and its potential breakthrough lung cancer treatment in a deal worth at least $5.8 billion in cash and stock, with the potential for another...To view the full article, register now.
Already a subscriber? Click here to view full article